Did retatrutide weight reduction plateau in the phase 2 trial?

The phase 2 registry outcomes show larger mean percent body-weight reductions at week 48 than at week 24 in every retatrutide arm (NCT04881760). A pooled phase 1 and 2 analysis stated that “the weight curves indicate that a plateau in weight loss was not reached” (PMID 39318607). The pooled analysis reported that a weight-loss plateau was not reached within its observation window (PMID 39318607).

Has tachyphylaxis been measured for retatrutide?

No. PubMed on 17 Sept 2026 returned 0 records for retatrutide AND tachyphylaxis and 0 for retatrutide AND (tolerance[tiab] OR loss of efficacy[tiab]). Tachyphylaxis of gastric-emptying delay was measured after four weekly subcutaneous tirzepatide doses (PMID 32519795, NCT02759107), not for retatrutide, and it has not been shown for retatrutide appetite or weight.

How many trial participants stayed below a 5% reduction?

One source reports that this pattern “affects approximately 10% of participants in controlled trials”, with higher shares in real-world cohorts (PMID 42634284). The same source describes early on-treatment response as “the most readily actionable predictor” (PMID 42634284).

Does retatrutide stop working over time? What trials show

Research use only. This page is scientific background and community-report context. Every compound sold here is supplied strictly for in-vitro research. Retatrutide is not authorized by the EMA or the FDA; it is an investigational compound. Nothing on this page is a protocol, a recommendation, or medical advice.

TL;DR: week 24, week 48, and what was never measured

Research question: does retatrutide stop working over time? What the published data say: in the 48-week phase 2 trial, the mean reduction in body weight was larger at week 48 than at week 24 in every registry arm (NCT04881760), and in a pooled analysis of phase 1 and 2 randomized trials “the weight curves indicate that a plateau in weight loss was not reached” (PMID 39318607). What has not been studied: PubMed on 17 Sept 2026 found 0 records for retatrutide AND tachyphylaxis and 0 for retatrutide AND (tolerance[tiab] OR loss of efficacy[tiab]). No retatrutide trial with posted results runs past 48 weeks. What research communities report: the documented search matched 849 of 87,002 question posts in the 12-month corpus and 12 of 956 posts in the separate delta corpus. Its patterns included plateau, stalled-effect, returning-appetite and returning-hunger terms. One delta match concerned a supplier ‘stalling’, so the counts are upper bounds. These are community reports, not evidence of frequency.

What did the trial measure at week 24 and week 48?

The phase 2 trial NCT04881760 reported mean percent change from baseline in body weight at both reads, and every retatrutide registry arm showed a larger mean reduction at week 48 than at week 24.

These are the study arms of the cited trials, not an application protocol for research vials. Participants (n = 338) were assigned to placebo or to one of the six retatrutide arms in the table, administered as a subcutaneous injection once weekly for 48 weeks (NCT04881760).

Registry arm	Week 24	Week 48	Placebo comparator (wk 24 / wk 48)
1 mg	-7.18%	-8.67%	-1.55% / -2.11%
4 mg (2 start)	-12.00%	-16.32%	-1.55% / -2.11%
4 mg	-13.80%	-17.83%	-1.55% / -2.11%
8 mg (2 start)	-16.64%	-21.72%	-1.55% / -2.11%
8 mg (4 start)	-18.26%	-23.88%	-1.55% / -2.11%
12 mg (2 start)	-17.39%	-24.22%	-1.55% / -2.11%

1 mg

Week 24: -7.18%
Week 48: -8.67%
Placebo comparator (wk 24 / wk 48): -1.55% / -2.11%

4 mg (2 start)

Week 24: -12.00%
Week 48: -16.32%
Placebo comparator (wk 24 / wk 48): -1.55% / -2.11%

4 mg

Week 24: -13.80%
Week 48: -17.83%
Placebo comparator (wk 24 / wk 48): -1.55% / -2.11%

8 mg (2 start)

Week 24: -16.64%
Week 48: -21.72%
Placebo comparator (wk 24 / wk 48): -1.55% / -2.11%

8 mg (4 start)

Week 24: -18.26%
Week 48: -23.88%
Placebo comparator (wk 24 / wk 48): -1.55% / -2.11%

12 mg (2 start)

Week 24: -17.39%
Week 48: -24.22%
Placebo comparator (wk 24 / wk 48): -1.55% / -2.11%

NEJM combines the two 4 mg and the two 8 mg groups, so its arms differ from the registry split above; at 48 weeks the least-squares mean percentage change was -8.7% (1 mg), -17.1% (4 mg), -22.8% (8 mg) and -24.2% in the 12-mg group, as compared with -2.1% with placebo (PMID 37366315). In the 12 mg registry arm, the share reaching a 15% or greater body-weight reduction rose from 70% at week 24 to 83% at week 48, versus 1% and 2% with placebo (NCT04881760).

Did the curves flatten before the trial ended?

Not in the pooled data: a pooled analysis of phase 1 and 2 randomized trials, mean change -10.66 kg, reported that “the weight curves indicate that a plateau in weight loss was not reached” (PMID 39318607). The pooled analysis reported that a weight-loss plateau was not reached within its observation window (PMID 39318607). Published phase 3 retatrutide weight data reach week 40 (PMID 42250575, NCT06354660).

Which effects weakened over time?

One measured retatrutide effect rose and then fell inside the 48-week trial: “Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter” (PMID 37366315). That is a heart-rate time course, not the weight endpoint.

Tachyphylaxis has been measured for a comparator, not for retatrutide (PubMed, 17 Sept 2026: retatrutide AND tachyphylaxis, 0 records). PeptidesDirect does not sell tirzepatide or semaglutide. In a tirzepatide phase 1 study (subcutaneous, once weekly, four weeks; PMID 32519795, NCT02759107), “after 4 weeks of repeated dosing there was evidence of tachyphylaxis” of gastric-emptying delay, while “GE delay, while diminished, was still apparent” on day 23, and the glucose effect was “greater at day 23 versus day 2, despite the tachyphylaxis of GE delay”. Neither finding has been shown for retatrutide appetite or weight.

What happened when comparator treatment stopped?

The data sheet’s ClinicalTrials.gov check on 17 Sept 2026 recorded no posted results for the retatrutide randomized-withdrawal study NCT06859268. In a semaglutide withdrawal trial (n = 803), change from week 20 to week 68 was -7.9% with continued treatment versus +6.9% after switching to placebo (PMID 33755728, NCT03548987). In a tirzepatide withdrawal trial (n = 670), change from week 36 to week 88 was -5.5% with continued treatment versus +14.0% after switching to placebo (PMID 38078870, NCT04660643). In the follow-up of a 68-week semaglutide trial (n = 327), the mean reduction was 17.3% at week 68, and participants had regained 11.6 percentage points by week 120 (PMID 35441470, NCT03548935).

What has nobody measured?

No published retatrutide study has measured tachyphylaxis, desensitization or loss of response, and none with posted results passes 48 weeks. PubMed, 17 Sept 2026: retatrutide AND tachyphylaxis, 0 records; retatrutide AND (tolerance[tiab] OR loss of efficacy[tiab]), 0; retatrutide AND 104 week, 0; retatrutide AND (desensitization OR desensitisation), 1 off-topic oral microbiome review (PMID 42734711). ClinicalTrials.gov the same day: 0 studies for retatrutide AND tachyphylaxis; 33 retatrutide-intervention studies, 2 with results, both phase 2 (NCT04881760, NCT04867785).

TRIUMPH-1 (NCT05929066, n = 2335) completed 6 Apr 2026 with hasResults false: its design paper is published (PMID 41090431), its results are not, and the registry lists a 24-week extension after 80 weeks of treatment. NCT06859268 (estimated n = 643) describes participants receiving weekly subcutaneous retatrutide for 80 weeks, followed by continued retatrutide or placebo for 36 weeks; primary completion is April 2028, with body-weight change assessed from week 0 to week 116. No results are posted.

Candidate mechanisms for a plateau are named without numbers: “adaptive thermogenesis ... leading to weight plateaus and regain” (PMID 40961927), with “no single dominant mechanism” (PMID 42083883). Roughly 10% of participants in controlled trials do not reach a 5% reduction, with higher shares in real-world cohorts, and “early on-treatment response is the most readily actionable predictor” (PMID 42634284).

Products mentioned

Retatrutidemetabolic

Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide that acts on three receptors at once: GLP-1, GIP and glucagon. Supplied as a lyophilized powder for in-vitro research, with a batch-specific third-party certificate of analysis.

Sources

ClinicalTrials.gov. NCT04881760. Mean Percent Change From Baseline in Body Weight, Baseline, Week 24 and Baseline, Week 48; Percentage of Participants Who Achieve >= 15% Body Weight Reduction.
PMID 37366315, NCT04881760. “At 48 weeks, the least-squares mean percentage change ... was -8.7% ... -22.8% ... and -24.2% in the 12-mg group, as compared with -2.1%”; “Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.”
PMID 39318607. “the weight curves indicate that a plateau in weight loss was not reached.” Pooled phase 1 and 2 randomized trials, mean change -10.66 kg.
PMID 42250575, NCT06354660. Published phase 3 retatrutide weight data reach week 40: “-11.5% (SE 0.7) with retatrutide 4 mg, -13.9% (0.8) with 9 mg, and -15.3% (0.8) with 12 mg, versus -2.6% (0.5)”, n = 537.
PMID 32519795, NCT02759107. “after 4 weeks of repeated dosing there was evidence of tachyphylaxis”; “GE delay, while diminished, was still apparent”; “greater at day 23 versus day 2, despite the tachyphylaxis of GE delay.”
PMID 33755728, NCT03548987. “from week 20 to week 68 was -7.9% vs +6.9% with the switch to placebo.”
PMID 38078870, NCT04660643. “from week 36 to week 88 was -5.5% with tirzepatide vs 14.0%.”
PMID 35441470, NCT03548935. “regained 11.6 (SD: 7.7) and 1.9 (SD: 4.8) percentage points of lost weight ... by week 120.”
PubMed, searched 17 Sept 2026. retatrutide AND tachyphylaxis: 0; retatrutide AND (tolerance[tiab] OR loss of efficacy[tiab]): 0; retatrutide AND 104 week: 0; retatrutide AND (desensitization OR desensitisation): 1, an off-topic oral microbiome review (PMID 42734711).
ClinicalTrials.gov API v2, searched 17 Sept 2026. query.intr=retatrutide: 33 studies; filter.advanced=AREA[HasResults]true: 2, both phase 2 (NCT04881760, NCT04867785); query.term=retatrutide AND tachyphylaxis: 0.
PMID 41090431. TRIUMPH-1 design paper.
ClinicalTrials.gov. NCT05929066. TRIUMPH-1, n = 2335, completed 6 Apr 2026, hasResults false; “after the placebo-controlled 80 week treatment period for an additional 24 weeks.”
ClinicalTrials.gov. NCT06859268. “SC for 80 weeks, then placebo administered SC for an additional 36 weeks”; “Percent Change from Baseline in Body Weight”, “Week 0, Week 116”; primary completion April 2028.
PMID 40961927. “adaptive thermogenesis ... leading to weight plateaus and regain.”
PMID 42083883. “no single dominant mechanism.”
PMID 42634284. “affects approximately 10% of participants in controlled trials”; “early on-treatment response is the most readily actionable predictor.”

Research use only. Retatrutide is supplied for in-vitro laboratory research, not for administration to a person or animal, and not as a medicine. Nothing in this article is a protocol, a recommendation, or medical advice.